Phaseline

Targets › TNFSF15

TNFSF15 (Tumor necrosis factor ligand superfamily member 15): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Immunology; next expected readout Jan 2027.

Cytokine that signals through TNFRSF25 receptor. Functions as a T-cell costimulator, that increases IL-2 responsiveness and secretion of pro-inflammatory cytokines which enhances T-cell activation, proliferation and the survival of activated T-cells. (UniProt, O95150)

Open in Phaseline: the race on TNFSF15, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiocadBCD-261
Anti-TL1A human monoclonal antibody
TNFSF15, TL1APhase 2Ulcerative Colitis (UC); Crohn's Disease (CD); HealthyJan 2027

Conditions

Ulcerative Colitis (UC) (1) Crohn's Disease (CD) (1) Healthy (1)

Modalities

small molecule (1)

Companies

Biocad (1)

Related targets

TL1A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.